Efficacy and safety of natural killer cell therapy in patients with solid tumors: a systematic review and meta-analysis

In 2020, global cancer statistics reported 19.3 million new cases and 10 million deaths annually, highlighting the urgent need for effective treatments. Current therapies, such as surgery, radiation, and chemotherapy, have limitations in comprehensively addressing solid tumor. Recent advances in can...

Full description

Saved in:

Bibliographic Details
Published in:	Frontiers in immunology Vol. 15; p. 1454427
Main Authors:	Park, Heesook, Kim, Gyurin, Kim, Najin, Ha, Sungyoen, Yim, Hyeonwoo
Format:	Journal Article
Language:	English
Published:	Switzerland Frontiers Media S.A 16-10-2024
Subjects:	Humans Immunology Immunotherapy, Adoptive - adverse effects Immunotherapy, Adoptive - methods killer cells Killer Cells, Natural - immunology Killer Cells, Natural - transplantation natural neoplasms Neoplasms - immunology Neoplasms - therapy NK cells review systematic Treatment Outcome NK cells natural review meta-analysis systematic neoplasms killer cells
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	In 2020, global cancer statistics reported 19.3 million new cases and 10 million deaths annually, highlighting the urgent need for effective treatments. Current therapies, such as surgery, radiation, and chemotherapy, have limitations in comprehensively addressing solid tumor. Recent advances in cancer biology and immuno-oncology, including CAR-T cell therapy, show promise but face efficacy challenges against solid tumors. This meta-analysis systematically reviewed studies from PubMed, Embase, Cochrane, and ClinicalTrials.gov databases up to May 2024 to evaluate the clinical efficacy and safety of unmodified NK cell therapies in solid tumors. The included trials focused on reporting objective response rates (ORR). Thirty-one trials involving 600 patients across various cancers (e.g., NSCLC, HCC, breast, ovarian) were analyzed. NK cell therapies demonstrated promising ORRs, particularly 72.3% in hepatocellular carcinoma, often in combination with local therapies. Safety profiles were favorable, with fatigue being the most common adverse event. NK cell therapies represent a promising treatment option for solid tumors, offering a viable alternative to genetically modified cell therapies like CAR-T. Further research is needed to optimize the clinical utility of NK cell therapy and integrate it effectively into standard cancer treatment regimens. https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42023438410, identifier CRD42023438410.
Bibliography:	SourceType-Scholarly Journals-1 ObjectType-Feature-2 ObjectType-Undefined-1 content type line 23 ObjectType-Article-3 Edited by: Massimiliano Petrini, Scientific Institute of Romagna for the Study and Treatment of Tumors (IRCCS), Italy Hiroshi Terunuma, Biotherapy Institute of Japan, Inc., Japan Reviewed by: Yuan Tian, Affiliated Hospital of Shandong University of Traditional Chinese Medicine, China Yanlin Yu, National Institutes of Health (NIH), United States
ISSN:	1664-3224 1664-3224
DOI:	10.3389/fimmu.2024.1454427